62.50p+4.00 (+6.84%)17 Jun 2021, 15:47
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Redx Pharma PLC Fundamentals

Company NameRedx Pharma PLCLast Updated2021-06-17
IndustryBiotechnologySectorHealthcare
Shares in Issue273.887 mMarket Cap£171.18 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.05EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.3443Debt Equity Ratio0.7256
Asset Equity Ration/aCash Equity Ration/a
Quick Ratio4.3624Current Ratio4.37
Price To Book Value7.5188ROCE0

Redx Pharma PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Redx Pharma PLC Company Financials

Assets202020192018
Tangible Assets£3.71 m£134,000.00£191,000.00
Intangible Assets£411,000.00£417,000.00£423,000.00
Investments000
Total Fixed Assets£4.12 m£551,000.00£614,000.00
Stocks000
Debtors£546,000.00£445,000.00£818,000.00
Cash & Equivalents£27.51 m£3.20 m£6.47 m
Other Assets000
Total Assets£33.59 m£6.36 m£10.32 m
Liabilities202020192018
Creditors within 1 year£10.93 m£4.87 m£3.95 m
Creditors after 1 year£19.97 m0£605,000.00
Other Liabilities000
Total Liabilities£30.90 m£4.87 m£4.55 m
Net assets£2.69 m£1.49 m£5.76 m
Equity202020192018
Called up share capital£1.95 m£1.26 m£1.26 m
Share Premium£37.19 m£33.26 m£33.26 m
Profit / Loss-£9.17 m-£6.33 m-£10.15 m
Other Equity£2.69 m£1.49 m£5.76 m
Preference & Minorities000
Total Capital Employed£2.69 m£1.49 m£5.76 m
Ratios202020192018
Debt Ratio£0.8800
Debt-to-Equity£7.4300
Assets / Equityn/an/an/a
Cash / Equityn/an/an/a
EPS-£0.05-£0.04-£0.06
Cash Flow202020192018
Cash from operating activities£395,000.00-£4.67 m-£17.18 m
Cashflow before financing£23.86 m-£2.80 m-£17.23 m
Increase in Cash£23.81 m-£2.77 m-£17.34 m
Income202020192018
Turnover£5.68 m£3.13 m£129,000.00
Cost of sales0£350,000.000
Gross Profit£5.68 m£2.78 m£129,000.00
Operating Profit-£8.20 m-£6.25 m-£10.17 m
Pre-Tax profit-£9.17 m-£6.33 m-£10.15 m

Redx Pharma PLC Company Background

SectorHealthcare
ActivitiesRedx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others.
Latest Interim Date7 Jun 2021
Latest Fiscal Year End Date27 Jan 2021

Redx Pharma PLC Directors

AppointedNamePosition
2021-06-01Mr. Iain Gladstone RossNon-Executive Director,Chairman
2018-02-19Dr. Frank Murdoch ArmstrongNon-Executive Director,Chairman
2020-12-21Mr. Peter Eric Presland Non-Executive Director,Chairman (Interim)
2018-02-19Mr. Norman MolyneuxNon-Executive Director
2018-02-19Dr. Neil David MurrayExecutive Director,Chief Executive Officer
2018-02-19Dr. Peter JacksonNon-Executive Director
2017-03-30Dr. Derek LindsayExecutive Director,Chief Operating Officer
2017-03-30Mr. Philip John TotteyExecutive Director,Chief Financial Officer
2017-04-20Mr. Peter McPartlandNon-Executive Director
2021-01-27Dr. Bernhard Jurgen KirschbaumNon-Executive Director
2020-03-17Mr. Dominic Nicholas Jackson Executive Director,Chief Financial Officer
2020-12-23Ms. Lisa Mary Whewell AnsonExecutive Director,Chief Executive Officer
2021-03-02Dr. James Robert MeadExecutive Director,Chief Financial Officer
2020-12-21Ms. Sarah Gordon WildNon-Executive Director

Redx Pharma PLC Contact Details

Company NameRedx Pharma PLC
AddressBlock 33, Mereside, Alderley Park, Macclesfield, SK10 4TG
Telephone+44 1625469900
Websitehttps://www.redxpharma.com

Redx Pharma PLC Advisors

StockbrokerWG Partners
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
Nominated AdviserCantor Fitzgerald Europe
Phone +44 2078947895
StockbrokerCantor Fitzgerald Europe
Phone+44 2078947895
SolicitorDWF LLP
Phone+44 1612283702
Fax+44 1618352407
RegistrarEquiniti Ltd.
Phone+44 1214157082